397 related articles for article (PubMed ID: 24283755)
41. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
Ribeiro AF; Pratcorona M; Erpelinck-Verschueren C; Rockova V; Sanders M; Abbas S; Figueroa ME; Zeilemaker A; Melnick A; Löwenberg B; Valk PJ; Delwel R
Blood; 2012 Jun; 119(24):5824-31. PubMed ID: 22490330
[TBL] [Abstract][Full Text] [Related]
42. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
[TBL] [Abstract][Full Text] [Related]
43. Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia.
Gale RE; Lamb K; Allen C; El-Sharkawi D; Stowe C; Jenkinson S; Tinsley S; Dickson G; Burnett AK; Hills RK; Linch DC
J Clin Oncol; 2015 Jun; 33(18):2072-83. PubMed ID: 25964253
[TBL] [Abstract][Full Text] [Related]
44. DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia.
Ferreira HJ; Heyn H; Vizoso M; Moutinho C; Vidal E; Gomez A; Martínez-Cardús A; Simó-Riudalbas L; Moran S; Jost E; Esteller M
Oncogene; 2016 Jun; 35(23):3079-82. PubMed ID: 26434589
[TBL] [Abstract][Full Text] [Related]
45. Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.
Herold T; Metzeler KH; Vosberg S; Hartmann L; Jurinovic V; Opatz S; Konstandin NP; Schneider S; Zellmeier E; Ksienzyk B; Graf A; Krebs S; Blum H; Cristina Sauerland M; Büchner T; Berdel WE; Wörmann BJ; Mansmann U; Hiddemann W; Bohlander SK; Spiekermann K; Greif PA
Genes Chromosomes Cancer; 2017 Jan; 56(1):75-86. PubMed ID: 27636548
[TBL] [Abstract][Full Text] [Related]
46. Acute myeloid leukaemia in a case with Tatton-Brown-Rahman syndrome: the peculiar
Hollink IHIM; van den Ouweland AMW; Beverloo HB; Arentsen-Peters STCJM; Zwaan CM; Wagner A
J Med Genet; 2017 Dec; 54(12):805-808. PubMed ID: 28432085
[TBL] [Abstract][Full Text] [Related]
47. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
Walter MJ; Ding L; Shen D; Shao J; Grillot M; McLellan M; Fulton R; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Kandoth C; Baty J; Westervelt P; DiPersio JF; Mardis ER; Wilson RK; Ley TJ; Graubert TA
Leukemia; 2011 Jul; 25(7):1153-8. PubMed ID: 21415852
[TBL] [Abstract][Full Text] [Related]
48. DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients.
Shivarov V; Gueorguieva R; Stoimenov A; Tiu R
Leuk Res; 2013 Nov; 37(11):1445-50. PubMed ID: 23962568
[TBL] [Abstract][Full Text] [Related]
49. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.
LaRochelle O; Bertoli S; Vergez F; Sarry JE; Mansat-De Mas V; Dobbelstein S; Dastugue N; Strzelecki AC; Cavelier C; Creancier L; Pillon A; Kruczynski A; Demur C; Sarry A; Huguet F; Huynh A; Récher C; Delabesse E
Oncotarget; 2011 Nov; 2(11):850-61. PubMed ID: 22081665
[TBL] [Abstract][Full Text] [Related]
50. Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin.
Martín I; Navarro B; Villamón E; Solano C; Serrano A; Calabuig M; Amat P; Domingo F; Abellán R; García F; Olivares MD; Chaves FJ; Tormo M; Hernández-Boluda JC
Exp Mol Pathol; 2018 Aug; 105(1):139-143. PubMed ID: 30017658
[TBL] [Abstract][Full Text] [Related]
51. Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia.
Ibrahem L; Mahfouz R; Elhelw L; Abdsalam EM; Soliman R
Blood Cells Mol Dis; 2015 Jan; 54(1):84-9. PubMed ID: 25172541
[TBL] [Abstract][Full Text] [Related]
52. DNMT3A mutations in acute myeloid leukemia.
Shah MY; Licht JD
Nat Genet; 2011 Mar; 43(4):289-90. PubMed ID: 21445072
[TBL] [Abstract][Full Text] [Related]
53. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
[TBL] [Abstract][Full Text] [Related]
54. Mutational analysis of DNMT3A gene in acute leukemias and common solid cancers.
Kim MS; Kim YR; Yoo NJ; Lee SH
APMIS; 2013 Feb; 121(2):85-94. PubMed ID: 23031157
[TBL] [Abstract][Full Text] [Related]
55. [Effects of DNMT3A gene mutations on prognosis of patients with acute myeloid leukemia: a meta-analysis].
Xi XP; Zeng LX; Yu FF; Liu HS
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2015 Mar; 44(2):197-203. PubMed ID: 26038140
[TBL] [Abstract][Full Text] [Related]
56. [DNMT3A gene mutations in acute myeloid leukemia].
Chen YM; Lu QY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1556-60. PubMed ID: 22169324
[TBL] [Abstract][Full Text] [Related]
57. Bioinformatics Analysis Identifies Key Genes and Pathways in Acute Myeloid Leukemia Associated with DNMT3A Mutation.
Chen S; Chen Y; Lu J; Yuan D; He L; Tan H; Xu L
Biomed Res Int; 2020; 2020():9321630. PubMed ID: 33299888
[TBL] [Abstract][Full Text] [Related]
58. RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with
Sidorova OA; Sayed S; Paszkowski-Rogacz M; Seifert M; Camgöz A; Roeder I; Bornhäuser M; Thiede C; Buchholz F
Cells; 2022 Mar; 11(5):. PubMed ID: 35269477
[No Abstract] [Full Text] [Related]
59. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.
Russler-Germain DA; Spencer DH; Young MA; Lamprecht TL; Miller CA; Fulton R; Meyer MR; Erdmann-Gilmore P; Townsend RR; Wilson RK; Ley TJ
Cancer Cell; 2014 Apr; 25(4):442-54. PubMed ID: 24656771
[TBL] [Abstract][Full Text] [Related]
60. DNMT3A in haematological malignancies.
Yang L; Rau R; Goodell MA
Nat Rev Cancer; 2015 Mar; 15(3):152-65. PubMed ID: 25693834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
